摘要
目的:对3种兰索拉唑三联疗法治疗幽门螺杆菌感染的方案进行经济学评价。方法:将85例经胃镜确诊为胃或十二指肠溃疡伴Hp阳性患者随机分为3组。LCA组,口服阿莫西林胶囊(A)1.0g,bid;LCF组,口服呋喃唑酮片(F)0.2g,bid;LCZ组,口服左氧氟沙星胶囊(Z)0.2g,bid,并且3组同时口服兰索拉唑(L)30mg,bid,克拉霉素颗粒剂(C)500mg,bid,疗程均为7日。三联治疗结束后再分别予以兰索拉唑30mg,qd,整个疗程为3周,采用药物经济学的成本-效果法进行分析。结果:3组Hp根除率和溃疡愈合率差异无显著性,但治疗成本不同。结论:LCF三联疗法成本最低,并且效果最好。
OBJECTIVE： To evaluate the cost-effectiveness of three kinds of lansoprazole-included triple therapies in the treatment of Helicobacter pylori （ Hp） infection. METHODS： 85 patients with stomach ulcer or duodenal ulcer confirmed gastroscopically associated with Hp-positive were randomly divided into 3 groups,i. e. LCA group received oral amoxicillin （A） 1. 0 g B. i. d; LCF group received oral furazolidone tablets （F） 0. 2 B. i. d,and LCZ group received oral levofloxacin capsules （Z） 0. 2 Bid. Meanwhile,the patients in all three groups received oral lansoprazole （L） 30 mg B. i. d and clarithromycin granules （ C） 500 mg B. i. d. After 3-week treatment,cost-effectiveness of the three schemes was analyzed. RESULTS： There was no significant difference in Hp eradication rate and ulcer healing rate among the 3 groups,but significant differences were noted across the 3 groups in treatment costs. CONCLUSION： LCF-included triple therapy is of the lowest cost yet best efficacy for Helicobacter pylori infection.
出处
《中国医院用药评价与分析》
2010年第5期455-456,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
兰索拉唑
幽门螺杆菌
成本-效果分析
药物经济学
Lansoprazole
Helicobacter pylori
Cost-effectiveness analysis
Pharmacoeconomics
